Theravance Biopharma (TBPH) EBITDA Margin (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly EBITDA Margin of 53.58% for Q1 2026, up 4022.0% year-over-year from 1.3% in Q1 2025, and down 222.87% quarter-over-quarter from 43.61% in Q4 2025.
Powered by 
Analysis
Theravance Biopharma (TBPH) EBITDA Margin (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported EBITDA Margin for 14 consecutive years, with 53.58% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 4022.0% year-over-year to 53.58%; the TTM figure through Mar 2026 stood at 1.23% (up 7811.0% YoY), while the FY2025 annual figure was 48.03%, up 2490.0% from the prior year.
- EBITDA Margin slipped to 53.58% in Q1 2026 per TBPH's latest filing, from 43.61% in the prior quarter.
- Across five years, EBITDA Margin topped out at 43.61% in Q4 2025 and bottomed at 291.77% in Q1 2022.
- Historically, EBITDA Margin has averaged 95.44% across 5 years, with a median of 73.44% in 2022.
- Annual changes were most pronounced in 2022 — EBITDA Margin soared 33292 bps — and 2025, when it plunged 1653 bps.
- Theravance Biopharma's EBITDA Margin stood at 119.0% in 2022, then jumped by 70 bps to 35.53% in 2023, then slumped by 38 bps to 49.06% in 2024, then soared by 189 bps to 43.61% in 2025, then slumped by 223 bps to 53.58% in 2026.
- Business Quant data shows TBPH's EBITDA Margin at 53.58% in Q1 2026, 43.61% in Q4 2025, and 32.29% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Theravance Biopharma | 882.99 Mn | 495.33 Mn | - | -39.93% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -39.93% |
| Mar 31, 2026 | -53.58% |
| Dec 31, 2025 | 43.61% |
| Sep 30, 2025 | -32.29% |
| Jun 30, 2025 | -10.40% |
| Mar 31, 2025 | -93.80% |
| Dec 31, 2024 | -49.06% |
| Sep 30, 2024 | -64.25% |
| Jun 30, 2024 | -110.16% |
| Mar 31, 2024 | -77.27% |
| Dec 31, 2023 | -35.53% |
| Sep 30, 2023 | -55.82% |
| Jun 30, 2023 | -117.27% |
| Mar 31, 2023 | -239.15% |
| Dec 31, 2022 | -119.00% |
| Sep 30, 2022 | -73.44% |
| Jun 30, 2022 | -243.25% |
| Mar 31, 2022 | -291.77% |
| Dec 31, 2021 | -375.80% |
| Sep 30, 2021 | -406.36% |